Literature DB >> 25561368

Systemic sclerosis in 2014: Advances in cohort enrichment shape future of trial design.

Yannick Allanore1, Oliver Distler2.   

Abstract

The treatment and study of systemic sclerosis (SSc) is entering a new era with the reporting and preparation of several randomized controlled trials according to an improved understanding of SSc pathogenesis. Advances in trial designs reported in 2014 should now be built upon with further improvements to patient selection to enable targeting of therapies to specific subgroups of patients with SSc.

Entities:  

Mesh：

Year:  2015        PMID： 25561368     DOI： 10.1038/nrrheum.2014.222

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

1.  Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

Authors:  P A Merkel; N P Silliman; P J Clements; C P Denton; D E Furst; M D Mayes; J E Pope; R P Polisson; J B Streisand; J R Seibold
Journal:  Arthritis Rheum       Date:  2012-10

2.  Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.

Authors:  Britta Maurer; Nicole Graf; Beat A Michel; Ulf Müller-Ladner; László Czirják; Christopher P Denton; Alan Tyndall; Carola Metzig; Vivian Lanius; Dinesh Khanna; Oliver Distler
Journal:  Ann Rheum Dis       Date:  2014-06-30       Impact factor: 19.103

Review 3.  Old medications and new targeted therapies in systemic sclerosis.

Authors:  Vivek Nagaraja; Christopher P Denton; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2014-07-26       Impact factor: 7.580

Review 4.  Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies.

Authors:  Mandana Nikpour; Murray Baron
Journal:  Curr Opin Rheumatol       Date:  2014-03       Impact factor: 5.006

5.  High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.

Authors:  P J Clements; D E Furst; W K Wong; M Mayes; B White; F Wigley; M H Weisman; W Barr; L W Moreland; T A Medsger; V Steen; R W Martin; D Collier; A Weinstein; E Lally; J Varga; S Weiner; B Andrews; M Abeles; J R Seibold
Journal:  Arthritis Rheum       Date:  1999-06

Review 6.  Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies.

Authors:  Muriel Elhai; Christophe Meune; Jérôme Avouac; André Kahan; Yannick Allanore
Journal:  Rheumatology (Oxford)       Date:  2011-09-07       Impact factor: 7.580

7.  Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.

Authors:  Richard K Burt; Sanjiv J Shah; Karin Dill; Thomas Grant; Mihai Gheorghiade; James Schroeder; Robert Craig; Ikuo Hirano; Karin Marshall; Eric Ruderman; Borko Jovanovic; Francesca Milanetti; Sandeep Jain; Kristin Boyce; Amy Morgan; James Carr; Walter Barr
Journal:  Lancet       Date:  2011-07-21       Impact factor: 79.321

8.  Prediction of pulmonary complications and long-term survival in systemic sclerosis.

Authors:  Svetlana I Nihtyanova; Benjamin E Schreiber; Voon H Ong; Daniel Rosenberg; Pia Moinzadeh; J Gerrard Coghlan; Athol U Wells; Christopher P Denton
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

Review 9.  Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.

Authors:  Tatiana Cobo-Ibáñez; Estíbaliz Loza-Santamaría; José María Pego-Reigosa; Alejandro Olivé Marqués; Iñigo Rúa-Figueroa; Antonio Fernández-Nebro; Rafael Cáliz Cáliz; Francisco Javier López Longo; Santiago Muñoz-Fernández
Journal:  Semin Arthritis Rheum       Date:  2014-04-13       Impact factor: 5.532

10.  Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.

Authors:  Jacob M van Laar; Dominique Farge; Jacob K Sont; Kamran Naraghi; Zora Marjanovic; Jérôme Larghero; Annemie J Schuerwegh; Erik W A Marijt; Madelon C Vonk; Anton V Schattenberg; Marco Matucci-Cerinic; Alexandre E Voskuyl; Arjan A van de Loosdrecht; Thomas Daikeler; Ina Kötter; Marc Schmalzing; Thierry Martin; Bruno Lioure; Stefan M Weiner; Alexander Kreuter; Christophe Deligny; Jean-Marc Durand; Paul Emery; Klaus P Machold; Francoise Sarrot-Reynauld; Klaus Warnatz; Daniel F P Adoue; Joël Constans; Hans-Peter Tony; Nicoletta Del Papa; Athanasios Fassas; Andrea Himsel; David Launay; Andrea Lo Monaco; Pierre Philippe; Isabelle Quéré; Éric Rich; Rene Westhovens; Bridget Griffiths; Riccardo Saccardi; Frank H van den Hoogen; Willem E Fibbe; Gérard Socié; Alois Gratwohl; Alan Tyndall
Journal:  JAMA       Date:  2014-06-25       Impact factor: 56.272
  10 in total
  10 in total

Review 1.  Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.

Authors:  Oliver Distler; Antonio Cozzio
Journal:  Semin Immunopathol       Date:  2015-11-17       Impact factor: 9.623

2.  IL4RA on lymphatic endothelial cells promotes T cell egress during sclerodermatous graft versus host disease.

Authors:  Katia Urso; David Alvarez; Viviana Cremasco; Kelly Tsang; Angelo Grauel; Robert Lafyatis; Ulrich H von Andrian; Joerg Ermann; Antonios O Aliprantis
Journal:  JCI Insight       Date:  2016-08-04

3.  Treatment of systemic sclerosis: is there any hope for the future?

Authors:  Yannick Allanore; Marco Matucci-Cerinic; Oliver Distler
Journal:  RMD Open       Date:  2016-07-04

4.  Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.

Authors:  Nadira Ruzehaji; Camelia Frantz; Matthieu Ponsoye; Jerome Avouac; Sonia Pezet; Thomas Guilbert; Jean-Michel Luccarini; Pierre Broqua; Jean-Louis Junien; Yannick Allanore
Journal:  Ann Rheum Dis       Date:  2016-03-09       Impact factor: 19.103

5.  Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine.

Authors:  Michelle Griffin; Caroline M Ryan; Omar Pathan; David Abraham; Christopher P Denton; Peter E M Butler
Journal:  Stem Cell Res Ther       Date:  2017-02-07       Impact factor: 6.832

6.  Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.

Authors:  Antonella Farina; Giovanna Peruzzi; Valentina Lacconi; Stefania Lenna; Silvia Quarta; Edoardo Rosato; Anna Rita Vestri; Michael York; David H Dreyfus; Alberto Faggioni; Stefania Morrone; Maria Trojanowska; G Alessandra Farina
Journal:  Arthritis Res Ther       Date:  2017-02-28       Impact factor: 5.156

Review 7.  Interleukin-33 in Systemic Sclerosis: Expression and Pathogenesis.

Authors:  Liya Li; Honglin Zhu; Xiaoxia Zuo
Journal:  Front Immunol       Date:  2018-11-15       Impact factor: 7.561

8.  Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay.

Authors:  Maurizio Cutolo; Stefano Soldano; Paola Montagna; Amelia Chiara Trombetta; Paola Contini; Barbara Ruaro; Alberto Sulli; Stefano Scabini; Emanuela Stratta; Sabrina Paolino; Carmen Pizzorni; Vanessa Smith; Renata Brizzolara
Journal:  Arthritis Res Ther       Date:  2018-07-27       Impact factor: 5.156

9.  Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study.

Authors:  Claudio Corallo; Maurizio Cutolo; Bashar Kahaleh; Gianluca Pecetti; Antonio Montella; Chiara Chirico; Stefano Soldano; Ranuccio Nuti; Nicola Giordano
Journal:  Arthritis Res Ther       Date:  2016-10-06       Impact factor: 5.156

10.  Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.

Authors:  Dinesh Khanna; Yannick Allanore; Christopher P Denton; Masataka Kuwana; Marco Matucci-Cerinic; Janet E Pope; Tatsuya Atsumi; Radim Bečvář; László Czirják; Eric Hachulla; Tomonori Ishii; Osamu Ishikawa; Sindhu R Johnson; Ellen De Langhe; Chiara Stagnaro; Valeria Riccieri; Elena Schiopu; Richard M Silver; Vanessa Smith; Virginia Steen; Wendy Stevens; Gabriella Szücs; Marie-Elise Truchetet; Melanie Wosnitza; Kaisa Laapas; Janethe de Oliveira Pena; Zhen Yao; Frank Kramer; Oliver Distler
Journal:  Ann Rheum Dis       Date:  2020-05       Impact factor: 27.973
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.